Reference number(s)
1720-H

SPECIALTY QUANTITY LIMIT PROGRAM

BOSULIF (bosutinib)

I. PROGRAM DESCRIPTION

The standard limit is designed to allow a quantity sufficient for the most common uses of the medication. The recommended dosing parameters for all FDA-approved indications fall within the standard limits. Coverage of an additional quantity may be reviewed on a case-by-case basis upon request.

II. COVERED QUANTITIES

Medication	Standard Limit	FDA-recommended dosing
Bosulif (bosutinib) 100 mg tablet	90 tablets per 30 days	Newly-diagnosed chronic phase Ph+ CML: 400 mg once daily Chronic, accelerated, or blast phase Ph+ CML with resistance or intolerance to prior therapy: 500 mg once daily
Bosulif (bosutinib) 400 mg tablet	30 tablets per 30 days	
Bosulif (bosutinib) 500 mg tablet	30 tablets per 30 days	

**Ph+: Philadelphia chromosome-positive; CML: chronic myelogenous leukemia*

III. REFERENCES

1. Bosulif [package insert]. New York, NJ: Pfizer Inc.; October 2018.

CVS caremark™